Maynard Um
-
-
-
-
-
-
-
Medicare finalizes coverage for CareDx transplant molecular tests
-
-
-
-
-
-
-
CareDx (CDNA) Tops Q1 EPS by 40c, provides guidance
-
-
-
-
-
-
-
CareDx partners with 10x Genomics on transplant rejection research program
-
-
-
-
-
-
-
CareDx submits comment on Medicare coverage policy for transplant testing
-
-
-
-
-
-
-
CareDx (CDNA) Announces Repurchase of 5% of Outstanding Shares
-
-
-
-
-
-
-
CareDx (CDNA) Announces Preliminary Fourth Quarter and Full Year 2024 Results
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on CareDx, Inc (CDNA)
-
439,327 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

